CD33 remains a valuable and clinically validated target for the therapy of CD33-positive subtypes of AML with antibody-derived agents [3-5], and consequently, several major drug developers currently study new agents for the treatment of AML with specificity for CD33. The gene discussed is CD33; the disease is acute myeloid leukemia.